Rosalind Franklin University Researcher Awarded NIH Funding to Investigate Links Between Down Syndrome and Alzheimer's Disease

2023-07-25

NORTH CHICAGO, ILLINOIS, July 25, 2023 — Research scientists at Rosalind Franklin University and New York University are teaming up in an attempt to generate new therapeutic approaches to combat the onset of Alzheimer’s disease (AD) in individuals with Down syndrome (DS), the most common chromosomal disorder and cause of intellectual disability. While individuals with DS are living longer, in part due to advances in medical science, more than 50-75% will develop dementia as they age, with many experiencing symptoms by their 40s, according to the National Institute on Aging. The institute has awarded Chicago Medical School investigator Dr. Grace E. Stutzmann $1.8 million — part of a $2.4 million grant in collaboration with Dr. Stephen D. Ginsberg of NYU’s Grossman School of Medicine. “We feel this is a powerful study that will greatly enlighten our understanding of how individuals with Down syndrome transition to Alzheimer’s through our combined strengths of transcriptomic analysis and neurophysiological mechanisms,” Dr. Stutzmann said. A professor and director of RFU’s Center for Neurodegenerative Disease and Therapeutics, Dr. Stutzmann has long studied the early neuronal pathology that develops in AD. Pathological hallmarks of AD include beta-amyloid and tau pathology, synaptic deficits, and neurodegeneration of key circuits underlying memory, attention and executive function. The extent to which these pathologies are found in DS are a significant component of the collaborative research project. “While DS and AD phenotypes overlap in many respects,” according to Dr. Stutzmann and Dr. Ginsberg, “the extent of shared pathophysiological mechanisms remains poorly understood. The knowledge gap is a potentially missed opportunity to arrest the onset of AD dementia in DS.” Dr. Stutzmann and RFU colleagues published a key AD paper in late 2022 in the scientific journal PNAS on “Protein mishandling and impaired lysosomal proteolysis generated through calcium dysregulation in Alzheimer's disease,” which provides the groundwork for possible shared mechanisms with DS and aligns with differentially expressed gene pathways identified by Dr. Ginsberg in vulnerable cell types that underlie memory and executive function. Ronald Kaplan, PhD, RFU executive vice president for research, commented: “We are pleased with Dr. Stutzmann’s collaboration with Dr. Ginsberg in studying the linkage of DS and AD patients with the goal of new therapeutic alternatives.” ROSALIND FRANKLIN UNIVERSITY encompasses six colleges and more than 10 research centers and institutes. Learn more at rosalindfranklin.edu.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构